These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 3893112

  • 1. Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporine.
    Kennedy MS, Deeg HJ, Storb R, Doney K, Sullivan KM, Witherspoon RP, Appelbaum FR, Stewart P, Sanders J, Buckner CD.
    Am J Med; 1985 Jun; 78(6 Pt 1):978-83. PubMed ID: 3893112
    [Abstract] [Full Text] [Related]

  • 2. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M, Perrin MC, Belhabri A, Molina L, Nicolini F, Tigaud JD, Sotto JJ, Guyotat D, Fière D, Archimbaud E.
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [Abstract] [Full Text] [Related]

  • 3. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation.
    Van Lint MT, Uderzo C, Locasciulli A, Majolino I, Scimé R, Locatelli F, Giorgiani G, Arcese W, Iori AP, Falda M, Bosi A, Miniero R, Alessandrino P, Dini G, Rotoli B, Bacigalupo A.
    Blood; 1998 Oct 01; 92(7):2288-93. PubMed ID: 9746766
    [Abstract] [Full Text] [Related]

  • 4. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.
    Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V.
    N Engl J Med; 1986 Mar 20; 314(12):729-35. PubMed ID: 3513012
    [Abstract] [Full Text] [Related]

  • 5. Cyclosporine and methylprednisolone for prophylaxis of acute graft-versus-host disease.
    Shepherd JD, Shore TB, Reece DE, Barnett MJ, Klingemann HG, Buskard NA, Phillips GL.
    Bone Marrow Transplant; 1988 Nov 20; 3(6):553-8. PubMed ID: 3063323
    [Abstract] [Full Text] [Related]

  • 6. Methylprednisolone, cyclosporine and methotrexate for prophylaxis of acute graft-versus-host disease.
    Yau JC, LeMaistre CF, Zagars GK, Williams LA, Meneghetti CM, Luke DR, Dunphy FR, Spinolo JA, Jagannath S, Spitzer G.
    Bone Marrow Transplant; 1990 Apr 20; 5(4):269-72. PubMed ID: 2337738
    [Abstract] [Full Text] [Related]

  • 7. Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graft-versus-host disease.
    Przepiorka D, Shapiro S, Schwinghammer TL, Bloom EJ, Rosenfeld CS, Shadduck RK, Venkataramanan R.
    Bone Marrow Transplant; 1991 Jun 20; 7(6):461-5. PubMed ID: 1873593
    [Abstract] [Full Text] [Related]

  • 8. Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone.
    Deeg HJ, Loughran TP, Storb R, Kennedy MS, Sullivan KM, Doney K, Appelbaum FR, Thomas ED.
    Transplantation; 1985 Aug 20; 40(2):162-6. PubMed ID: 3895622
    [Abstract] [Full Text] [Related]

  • 9. Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study.
    Ruutu T, Volin L, Parkkali T, Juvonen E, Elonen E.
    Blood; 2000 Oct 01; 96(7):2391-8. PubMed ID: 11001889
    [Abstract] [Full Text] [Related]

  • 10. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial.
    Deeg HJ, Lin D, Leisenring W, Boeckh M, Anasetti C, Appelbaum FR, Chauncey TR, Doney K, Flowers M, Martin P, Nash R, Schoch G, Sullivan KM, Witherspoon RP, Storb R.
    Blood; 1997 May 15; 89(10):3880-7. PubMed ID: 9160697
    [Abstract] [Full Text] [Related]

  • 11. Microangiopathy following allogeneic marrow transplantation. Association with cyclosporine and methylprednisolone for graft-versus-host disease prophylaxis.
    Kalhs P, Brugger S, Schwarzinger I, Greinix HT, Keil F, Kyrle PA, Knöbl P, Schneider B, Höcker P, Linkesch W.
    Transplantation; 1995 Nov 15; 60(9):949-57. PubMed ID: 7491699
    [Abstract] [Full Text] [Related]

  • 12. A randomized study of cyclosporine and methotrexate with or without methylprednisolone for the prevention of graft-versus-host disease: Improved long-term survival with triple prophylaxis.
    Ruutu T, Nihtinen A, Niittyvuopio R, Juvonen E, Volin L.
    Cancer; 2018 Feb 15; 124(4):727-733. PubMed ID: 29112242
    [Abstract] [Full Text] [Related]

  • 13. Graft-versus-host-disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone.
    Leelasiri A, Greer JP, Stein RS, Goodman S, Brandt SA, Edwards JR, Wolff SN.
    Bone Marrow Transplant; 1995 Mar 15; 15(3):401-5. PubMed ID: 7599565
    [Abstract] [Full Text] [Related]

  • 14. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease.
    Storb R, Deeg HJ, Farewell V, Doney K, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Hansen J.
    Blood; 1986 Jul 15; 68(1):119-25. PubMed ID: 3521761
    [Abstract] [Full Text] [Related]

  • 15. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group.
    Frickhofen N, Kaltwasser JP, Schrezenmeier H, Raghavachar A, Vogt HG, Herrmann F, Freund M, Meusers P, Salama A, Heimpel H.
    N Engl J Med; 1991 May 09; 324(19):1297-304. PubMed ID: 2017225
    [Abstract] [Full Text] [Related]

  • 16. [Cyclosporine as prophylaxis for graft versus host disease in adults undergoing allogeneic bone marrow transplantation].
    Matsushita T, Akatsuka Y, Towatari M, Takeyama K, Miyamura K, Sugihara T, Minami S, Kodera Y.
    Rinsho Ketsueki; 1989 Apr 09; 30(4):429-36. PubMed ID: 2671437
    [Abstract] [Full Text] [Related]

  • 17. Muromonab-CD3 (Orthoclone OKT3), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation.
    Benekli M, Hahn T, Williams BT, Cooper M, Roy HN, Wallace P, Stewart C, Bambach B, McCarthy PL.
    Bone Marrow Transplant; 2006 Sep 09; 38(5):365-70. PubMed ID: 16862164
    [Abstract] [Full Text] [Related]

  • 18. High-dose methylprednisolone treatment for acute graft-versus-host disease after bone marrow transplantation in adults.
    Kanojia MD, Anagnostou AA, Zander AR, Vellekoop L, Spitzer G, Verma DS, Jagannath S, Dicke KA.
    Transplantation; 1984 Mar 09; 37(3):246-9. PubMed ID: 6367162
    [Abstract] [Full Text] [Related]

  • 19. Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention.
    Sayer HG, Longton G, Bowden R, Pepe M, Storb R.
    Blood; 1994 Aug 15; 84(4):1328-32. PubMed ID: 8049448
    [Abstract] [Full Text] [Related]

  • 20. Low incidence of severe acute and chronic graft-versus-host disease as a result of prolonged cyclosporine prophylaxis and early aggressive treatment with corticosteroids.
    Ruutu T, Volin L, Elonen E.
    Transplant Proc; 1988 Jun 15; 20(3):491-3. PubMed ID: 3289191
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.